Anti-angiogenic effect of auranofin on HUVECs in vitro and zebrafish in vivo

European Journal of Pharmacology

Volumn 740, Issue , 2014, Pages 240-247

  He, Ming Fang ^a   Gao, Xiao Ping ^a   Li, Shu Chun ^a   He, Zhi Heng ^b   Chen, Ning ^a   Wang, Yu Bin ^a   She, Jin Xiong ^a,c  

^a NANJING TECH UNIVERSITY   (China)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Angiogenesis inhibitor; Auranofin; HUVEC; Zebrafish

Indexed keywords

ANGIOGENESIS INHIBITOR; AURANOFIN; FLT1 PROTEIN, ZEBRAFISH; THIOREDOXIN REDUCTASE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VEGF PROTEIN, ZEBRAFISH; ZEBRAFISH PROTEIN;

ANIMAL; ANIMAL EMBRYO; BLOOD VESSEL; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; EMBRYOLOGY; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; ZEBRA FISH;

ANGIOGENESIS INHIBITORS; ANIMALS; AURANOFIN; BLOOD VESSELS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; EMBRYO, NONMAMMALIAN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; THIOREDOXIN-DISULFIDE REDUCTASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84905507236     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.07.034     Document Type: Article

References (34)

1. S. Basu, and C. Sachidanandan Zebrafish: a multifaceted tool for chemical biologists Chem. Rev. 113 2013 7952 7980
2. R.C. Blodgett Jr. Auranofin: experience to date Am. J. Med. 75 1983 86 89 (Pubitemid 14183626)
3. J. Bussmann, N. Lawson, L. Zon, S. Schulte-Merker, and C. Zebrafish Nomenclature Zebrafish VEGF receptors: a guideline to nomenclature PLoS Genet. 4 2008 e1000064
4. J.E. Cannon, P.D. Upton, J.C. Smith, and N.W. Morrell Intersegmental vessel formation in zebrafish: requirement for VEGF but not BMP signalling revealed by selective and non-selective BMP antagonists Br. J. Pharmacol. 161 2010 140 149
5. A. Casini, and L. Messori Molecular mechanisms and proposed targets for selected anticancer gold compounds Curr. Top. Med. Chem. 11 2011 2647 2660
6. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat. Med. 1 1995 27 31
7. X.P. Gao, F. Feng, X.Q. Zhang, X.X. Liu, Y.B. Wang, J.X. She, Z.H. He, and M.F. He Toxicity assessment of seven anticancer compounds in zebrafish Int. J. Toxicol. 33 2014 98 105
8. J. Garcia-Quiroz, M. Rivas-Suarez, R. Garcia-Becerra, D. Barrera, I. Martinez-Reza, D. Ordaz-Rosado, N. Santos, O. Villanueva, C.L. Santos-Cuevas, E. Avila, A. Gamboa-Dominguez, A. Halhali, F. Larrea, and L. Diaz Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis J. Steroid Biochem. Mol. Biol. 2013 10.1016/j.jsbmb.2013.09.019
9. K. Goishi, and M. Klagsbrun Vascular endothelial growth factor and its receptors in embryonic zebrafish blood vessel development Curr. Top. Dev. Biol. 62 2004 127 152 (Pubitemid 39752377)
10. K. Hashimoto, C.E. Whitehurst, T. Matsubara, K. Hirohata, and P.E. Lipsky Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C J. Clin. Investig. 89 1992 1839 1848
11. M.F. He, Y.H. Huang, L.W. Wu, W. Ge, P.C. Shaw, and P.P. But Triptolide functions as a potent angiogenesis inhibitor Int. J. Cancer 126 2010 266 278
12. M.F. He, L. Liu, W. Ge, P.C. Shaw, R. Jiang, L.W. Wu, and P.P. But Antiangiogenic activity of Tripterygium wilfordii and its terpenoids J. Ethnopharmacol. 121 2009 61 68
13. Z.H. He, M.F. He, S.C. Ma, and P.P. But Anti-angiogenic effects of rhubarb and its anthraquinone derivatives J. Ethnopharmacol. 121 2009 313 317
14. Z.H. He, R. Zhou, M.F. He, C.B. Lau, G.G. Yue, W. Ge, and P.P. But Anti-angiogenic effect and mechanism of rhein from Rhizoma Rhei Phytomedicine 18 2011 470 478
15. M. Jansen, P.C. de Witt Hamer, A.N. Witmer, D. Troost, and C.J. van Noorden Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas Brain Res. Brain Res. Rev. 45 2004 143 163 (Pubitemid 38802868)
16. I.K. Lam, D. Alex, Y.H. Wang, P. Liu, A.L. Liu, G.H. Du, and S.M. Lee In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: identifying sinensetin as a novel antiangiogenesis agent Mol. Nutr. Food Res. 56 2012 945 956
17. K.H. Lam, D. Alex, I.K. Lam, S.K. Tsui, Z.F. Yang, and S.M. Lee Nobiletin, a polymethoxylated flavonoid from citrus, shows anti-angiogenic activity in a zebrafish in vivo model and HUVEC in vitro model J. Cell. Biochem. 112 2011 3313 3321
18. J.A. Lessa, J.C. Guerra, L.F. de Miranda, C.F. Romeiro, J.G. Da Silva, I.C. Mendes, N.L. Speziali, E.M. Souza-Fagundes, and H. Beraldo Gold(I) complexes with thiosemicarbazones: cytotoxicity against human tumor cell lines and inhibition of thioredoxin reductase activity J. Inorg. Biochem. 105 2011 1729 1739
19. A. Letamendia, C. Quevedo, I. Ibarbia, J.M. Virto, O. Holgado, M. Diez, J.C. Izpisua Belmonte, and C. Callol-Massot Development and validation of an automated high-throughput system for zebrafish in vivo screenings PloS One 7 2012 e36690
20. D. Li, X.P. Li, H.X. Wang, Q.Y. Shen, X.P. Li, L. Wen, X.J. Qin, Q.L. Jia, H.F. Kung, and Y. Peng VEGF induces angiogenesis in a zebrafish embryo glioma model established by transplantation of human glioma cells Oncol. Rep. 28 2012 937 942
21. J.M. Madeira, D.L. Gibson, W.F. Kean, and A. Klegeris The biological activity of auranofin: implications for novel treatment of diseases Inflammopharmacology 20 2012 297 306
22. A. Mantovani Molecular pathways linking inflammation and cancer Curr. Mol. Med. 10 2010 369 373
23. C. Marzano, V. Gandin, A. Folda, G. Scutari, A. Bindoli, and M.P. Rigobello Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells Free Radic. Biol. Med. 42 2007 872 881 (Pubitemid 46274171)
24. A. Nakaya, M. Sagawa, A. Muto, H. Uchida, Y. Ikeda, and M. Kizaki The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity Leuk. Res. 35 2011 243 249
25. A.K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh VEGF receptor signalling - in control of vascular function Nat. Rev. Mol. Cell Biol. 7 2006 359 371
26. I. Ott, X. Qian, Y. Xu, D.H. Vlecken, I.J. Marques, D. Kubutat, J. Will, W.S. Sheldrick, P. Jesse, A. Prokop, and C.P. Bagowski A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor J. Med. Chem. 52 2009 763 770
27. M. Shibuya, and L. Claesson-Welsh Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis Exp. Cell Res. 312 2006 549 560 (Pubitemid 43290332)
28. R.M. Snyder, C.K. Mirabelli, and S.T. Crooke The cellular pharmacology of auranofin Semin. Arthritis Rheum. 17 1987 71 80 (Pubitemid 17135785)
29. K.L. Streicher, M.J. Sylte, S.E. Johnson, and L.M. Sordillo Thioredoxin reductase regulates angiogenesis by increasing endothelial cell-derived vascular endothelial growth factor Nutr. Cancer 50 2004 221 231
30. Z. Szekanecz, and A.E. Koch Targeting angiogenesis in rheumatoid arthritis Curr. Rheumatol Rev. 4 2008 298 303
31. Kondoa Takako, Ohtaa Toshiro, Iguraa Koichi, Harab Yukihiko, and K. Kaji Tea catechins inhibit angiogenesis in vitro, measured by human Cancer Lett. 180 2002 139 144
32. K. Venardos, G. Harrison, J. Headrick, and A. Perkins Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart Clin. Exp. Pharmacol. Physiol. 31 2004 289 294 (Pubitemid 38803070)
33. M. Westerfield The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish 5 ed. 2007 The University of Oregon Press Eugene, OR
34. M.L. Wong, A. Prawira, A.H. Kaye, and C.M. Hovens Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas J. Clin. Neurosci. 16 2009 1119 1130